Open Nav

Isaac Bright


RubrYc Therapeutics, Inc.

Dr. Bright started his career as Financial Analyst at CIBC World Markets in 2004. He joined the Medtronic Corporate Development team in 2006, and quickly progressed to become Director of Business Development for Medtronic Neuromodulation in 2008. Subsequently, Dr. Bright joined the leadership team of QuantaLife, Inc. in 2009 and drove the Company’s financing, BD, and successful trade-sale to Bio-Rad Laboratories in 2011. Dr. Bright spent more than 4 years as a VC investor, serving as the only American Partner for Merieux Developpement, with €220M under management. In 2016, Isaac served as VP, Corporate Development for Synthetic Biologics, before supporting Muse bio's $23M Series B financing in early 2017. Dr. Bright joined HealthTell as CBO in April 2017, and drove the Company's merger with PatientsLikeMe and iCarbonX, concomitatn with the $10M Series A spin-out of RubrYc Therapeutics.

Dr. Bright earned his MD at Stanford and MBA at The Wharton School.

This speaker's sessions: